SkylineDx develops and markets gene signature-based prognostic tests that assist healthcare professionals in making personalized treatment decisions. MMprofiler™ with SKY92, the company’s lead product in Europe, is a gene-based risk identification signature that determines the level of risk for patients with multiple myeloma by classifying them into a “high” or “standard” risk group. The performance of the SKY92 gene signature exceeds that of standard clinical parameters utilized in myeloma.